MétaCan
Menu
Back to cohort

Abstract IA022: DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq/11-specific inhibitor for the treatment of metastatic uveal melanoma

2024· article· en· W4405181578 on OpenAlexaboutno aff
Josephzore Wk, Joseph A. D’Alessio, Padmaja Yerramilli-Rao, John Blankenship, Kathrin Buntin, M. Bürger, Zhuoliang Chen, Young Shin Cho, John C. Davis, Nicolas Ebel, Jochen Eisfeld, Anne Haberkorn, Dominik Hainzl, Keith Hoffmaster, Matthias Napp, Dominik Pistorius, Vivek Rauniyar, Vincent Romanet, Christian Schnell, Katherine Seiss, William R. Tschantz, Susanne Wieland-Berghausen, Laurin Wimmer, Kuno Wuersch, Alan Zhang, Eusebio Manchado

Bibliographic record

VenueMolecular Cancer Therapeutics · 2024
Typearticle
Languageen
FieldMedicine
TopicMonoclonal and Polyclonal Antibodies Research
Canadian institutionsnot available
Fundersnot available
KeywordsGNAQCancer researchMelanomaAntibody-drug conjugateCancerIn vivoMedicineAntibodyBiologyMonoclonal antibodyInternal medicineImmunologyMutation

Abstract

fetched live from OpenAlex

Abstract Activating mutations in GNAQ/GNA11, encoding the G protein α subunits Gq and G11, are the most frequent genetic alterations in uveal melanoma (UVM) and considered to be critical for the initiation and maintenance of this malignancy. Despite inhibitors of Gq and G11 exhibiting promising preclinical anti-uveal melanoma activity, their therapeutic potential is limited by on-target toxicities associated with the ubiquitous expression and critical biological processes mediated by these G proteins. Here we report the discovery of a novel Gq/11 inhibitor-based antibody-drug-conjugate (ADC), DYP688, that selectively targets UVM cells, while sparing normal Gq/11-dependent cells. This conjugate consists of the highly potent and selective Gq/11 inhibitor SDZ475 (FR900359) conjugated to an antibody targeting PMEL17, a lineage gene having significant differential expression in melanoma. DYP688 potently inhibits Gq/11 oncogenic signaling, resulting in selective antiproliferative activity and apoptosis in PMEL17-positive, GNAQ/11-mutant UVM cells. In vivo, DYP688 exhibits marked and durable tumor regression in GNAQ/11-mutant UVM models, including patient-derived xenograft and liver metastasis models. Finally, we show that DYP688 features favorable preclinical pharmacokinetic and safety profiles, supportive of clinical evaluation. A phase 1 clinical trial with DYP688 is currently ongoing to assess the safety, tolerability and preliminary anti-tumor activity in patients with metastatic UVM and other GNAQ/11-mutant melanomas (clinicaltrials.gov identifier NCT05415072). Citation Format: Josephzore Wk, Joseph A. D'Alessio, Padmaja Yerramilli-Rao, John Blankenship, Kathrin Buntin, Matthew Burger, Zhuoliang Chen, Young Shin Cho, John Davis, Nicolas Ebel, Jochen Eisfeld, Anne Haberkorn, Dominik Hainzl, Keith Hoffmaster, Matthias Napp, Dominik Pistorius, Vivek Rauniyar, Aimee Reynolds, Vincent Romanet, Christian Schnell, Katherine Seiss, William R. Tschantz, Susanne Wieland-Berghausen, Laurin Wimmer, Kuno Wuersch, Alan Zhang, Eusebio Manchado. DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq/11-specific inhibitor for the treatment of metastatic uveal melanoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry; 2024 Dec 9-11; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(12_Suppl):Abstract nr IA022.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.691
Threshold uncertainty score0.809

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.044
GPT teacher head0.347
Teacher spread0.303 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicMonoclonal and Polyclonal Antibodies ResearchFrench-language works237,207